@prefix this: <http://bio2rdf.org/drugbank_resource:DB00582_DB06145_nanopub.RAZWH8jbQtUq0HD5ycujjJ5R8usHKrCW3lmJBw8upo6rI> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00582_DB06145_nanopub.RAZWH8jbQtUq0HD5ycujjJ5R8usHKrCW3lmJBw8upo6rI#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB00582 dv:ddi-interactor-in dr:DB00582_DB06145 .
  
  d:DB06145 dv:ddi-interactor-in dr:DB00582_DB06145 .
  
  dr:DB00582_DB06145 dct:identifier "drugbank_resource:DB00582_DB06145";
    dct:title "DDI between Voriconazole and Spiramycin - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of spiramycin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of spiramycin if voriconazole is initiated, discontinued or dose changed."@en;
    a dv:Drug-Drug-Interaction;
    rdfs:label "DDI between Voriconazole and Spiramycin - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of spiramycin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of spiramycin if voriconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00582_DB06145]"@en .
}

sub:provenance {
  sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MCwCFAWQ1Ok-fxVc npx:hasPublicKey "MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y=";
    npx:hasSignature "MCwCFAWQ1Ok+fxVcY5KHA7HSC3uuoN4aAhRdSdkpuy8u835WX8hO3HmEGFC/CA==";
    npx:signedBy instance: .
  
  this: dct:created "2018-03-30T11:12:56.740+02:00"^^xsd:dateTime;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFAWQ1Ok-fxVc;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dct:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dct:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}